Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ultragenyx Pharmaceu (NQ: RARE )

51.58 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 51.69 (2)
Ask (Size) 53.95 (1)
Prev. Close 51.58
Today's Range 51.58 - 51.58
52wk Range 33.36 - 68.68
Shares Outstanding 70,814,462
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ultragenyx to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
The Latest Analyst Ratings for Ultragenyx Pharmaceutical
 
Via Benzinga

Performance

YTD
+13.31%
+13.31%
1 Month
+9.58%
+9.58%
3 Month
+29.21%
+29.21%
6 Month
+25.16%
+25.16%
1 Year
-5.17%
-5.17%

More News

Read More
Benzinga's Top Ratings Upgrades, Downgrades For June 6, 2023
Via Benzinga
Why Ultragenyx Pharma Stock Is Trading Higher Premarket Today
Via Benzinga
Ultragenyx Pharmaceutical's Return On Capital Employed Insights
Via Benzinga
Ultragenyx Pharmaceutical: Q1 Earnings Insights
Via Benzinga
Apple To Rally Around 17%? Here Are 10 Other Analyst Forecasts For Tuesday
Via Benzinga
Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Present at the 2023 Barclays - Gene Editing & Gene Therapy Summit
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
A Preview Of Ultragenyx Pharmaceutical's Earnings
Via Benzinga
Expert Ratings for Ultragenyx Pharmaceutical
Via Benzinga
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
Via MarketBeat
Exposures Product Safety
Ultragenyx Receives FDA Agreement to Expand Ongoing Global Phase 1/2 Trial Evaluating GTX-102 in Patients with Angelman Syndrome in the U.S.
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Pharm Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
Via Investor's Business Daily
Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Present at Bank of America’s 2023 Health Care Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports First Quarter 2023 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Host Conference Call for First Quarter 2023 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 26, 2023
Via Benzinga
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
7 Biotech Stocks to Buy for Breakthrough Treatments and Cures
Via InvestorPlace
Ultragenyx to Present at Guggenheim’s Genomic Medicines and Rare Disease Days
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.